DRUG Act Delinking Revenue from Unfair Gouging Act
Impact
If enacted, HB2214 would significantly alter the financial relationships between PBMs and health care entities. By disallowing remuneration based on drug prices, discounts, or rebates, the legislation would push PBMs to operate on a fee-for-service basis, where fees must be fair and transparent. This may lead to a reduction in overall healthcare costs for patients as the financial conflicts of interest that can contribute to inflated drug prices are minimized. However, it may also lead to uncertainties regarding the operational viability of some PBMs that depend on revenue generated from negotiated discounts and rebates.
Summary
House Bill 2214, also known as the Delinking Revenue from Unfair Gouging Act (DRUG Act), aims to reform the operations of pharmacy benefit managers (PBMs) by prohibiting them from receiving any remuneration from entities concerning services related to prescription drug benefits under group health plans. This change is set to take effect on January 1, 2027, and seeks to improve transparency and fairness in how drugs are priced and accessed within the healthcare system. The bill emphasizes the role of PBMs in negotiating and administering prescription benefits and addresses concerns regarding the financial incentives that may lead to higher drug prices for consumers.
Contention
The bill could face contention from various stakeholders. Supporters argue that this reform will help lower prescription drug costs and protect consumers from unjust price increases motivated by profit-seeking behavior among PBMs. On the other hand, opponents may raise concerns regarding the potential for reduced services or slower access to therapies if PBMs lose revenue that helps fund their operations. Further discussions are likely needed to balance the interests of fair drug pricing with the operational realities of pharmacy benefit management.